Rating date
May 29, 2026
73 days ago
Intuitive Surgical (ISRG) Stock Analysis
HOLDISRG Equity Research — HOLD — May 2026
Desk view
HOLD
5D move
—
Neutral (HOLD unscored)
Peer rank
14p
Research history
2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 moreInvestment card · ISRG
1. ISRG’s price trend is decisively bearish, with lower highs and lower lows since May 2025.
Desk rating
HOLD
Tactical HOLD · 12M HOLD
Horizon
Long-term
Confidence
Medium
Invalidation
If the stock breaks decisively above the 20-day SMA ($438) and then the 50-day (not given) and 200-day ($496 from your argument?) on increasing volume, I'd reconsider. If an insider makes an open-market purchase — even one — that would signal confidence. If forward guidance accelerates procedure growth above 20% instead of decelerating, I'd listen. Until then, the evidence stack says: downtrend intact, valuation rich, insider selling, macro soft, consensus optimistic but not proven. I'm skeptical.
Bias
HOLD
Catalysts
- ISRG’s price trend is decisively bearish, with lower highs and lower lows since May 2025.
- Momentum indicators (RSI, MACD) are negative but not at extreme levels, leaving room for further declines.
- Volatility (ATR) is elevated, suggesting that stop‑loss placement and position sizing should allow for wide daily ranges.
Risks
- Event-driven repricing risk if expectations diverge from incoming evidence.
Market chart
Price context alongside the research narrative.
ISRG Research Note
Full desk note for May 29, 2026. Use tabs for catalysts, valuation and risks, or open the full note.
WebserviceX · Agentic Research Desk
ISRG Equity Research Note
ISRG Stock Rating Summary
ISRG bias
HOLD
Horizon
Long-term
ISRG key risk
Event-driven repricing risk if expectations diverge from incoming evidence.
ISRG catalyst watch
ISRG’s price trend is decisively bearish, with lower highs and lower lows since May 2025.
Invalidation
If the stock breaks decisively above the 20-day SMA ($438) and then the 50-day (not given) and 200-day ($496 from your argument?) on increasing volume, I'd reconsider. If an insider makes an open-market purchase — even one — that would signal confidence. If forward guidance accelerates procedure growth above 20% instead of decelerating, I'd listen. Until then, the evidence stack says: downtrend intact, valuation rich, insider selling, macro soft, consensus optimistic but not proven. I'm skeptical.
Confidence
Medium
How the call aged · 5D
—Neutral (HOLD unscored)Peer 14pExpandCollapse
How the call aged · 5D
—Neutral (HOLD unscored)Peer 14p
Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-05-30T11:24:20.421580+00:00.
5D move
—
2026-05-29 → awaiting
Outcome
Neutral (HOLD unscored)
5D trend
-3.45%
Vol (20D ann.)
+35.81%
vs SPY: -5.30%
Close 424.64 → — (USD, vendor closes)
Batch scorecard · 2026-05-29 · ISRG